Effect of bolesatine, a glycoprotein from Boletus satanas, on rat thymus in vivo.
Bolesatine is a glycoprotein purified to homogeneity from Boletus satanas Lenz, a toxic mushroom which causes serious gastroenteritis. This lectin possesses a mitogenic activity on human lymphocytes at very low concentrations, whereas higher concentrations inhibit protein synthesis in vitro in several systems. The mitogenic activity on peripheral blood T lymphocytes in vitro has been shown to be at least 200-fold higher than the activity of the well studied phytohemagglutinin (PHA). In order to verify this property in vivo, the effect of bolesatine has been studied in thymus of rats given orally bolesatine. Two groups of bolesatine-treated animals were used in addition to the control group. One group was given every 48 h, 28 micrograms of bolesatine/kg body weight seven times and 150 micrograms/kg body weight 48 h before the sacrifice. The other group was given 55 micrograms of bolesatine/kg body weight according to the same protocol and 150 micrograms/kg body weight 48 h before the sacrifice. In these conditions, the ratio thymus weight/body weight is increased by 10% and 28%, respectively, in groups 1 and 2. Similarly, the DNA synthesis is increased by more than 50%, indicating that (i) bolesatine probably possesses a mitogenic effect on thymocytes in vivo (ii) that the increase of the ratio thymus weight/body weight is not due to swelling by water retention, but rather to a multiplication of thymocytes. These results are confirmed in a second run of experiments in which bolesatine given orally to rats in lower doses of 3-12 micrograms/kg induces an increase of both thymus weight by 47% to 54% and an increase of total proteins by 52% to 56%, respectively, whereas the ratio total protein/g of thymus does not change. Thus bolesatine, known to be mitogenic to human lymphocytes in vitro is also mitogenic to rat thymocytes in vivo.
Ennamany
R
R
Laboratoire de Toxicologie et d' Hygiène Appliquée, Universit de Bordeaux, France.
Kretz
O
O
Badoc
A
A
Deffieux
G
G
Creppy
E E
EE
D000284:Administration, Oral; D000818:Animals; D001487:Basidiomycota / Q000737:chemistry; D001835:Body Weight / Q000187:drug effects; D004247:DNA / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D005656:Fungal Proteins / Q000008:administration & dosage / Q000302:isolation & purification / Q000633:toxicity*; D008297:Male; D009183:Mycotoxins / Q000008:administration & dosage / Q000302:isolation & purification / Q000633:toxicity*; D009929:Organ Size / Q000187:drug effects; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D013936:Thymidine / Q000378:metabolism; D013950:Thymus Gland / Q000187:drug effects* / Q000378:metabolism
D005656:Fungal Proteins; D009183:Mycotoxins; C060924:Bolesatine protein, Boletus satanas; D004247:DNA; D013936:Thymidine